Literature DB >> 2256164

Angiogenic peptides in pancreatic islet transplantation to diabetic rats.

A Hayek1, A D Lopez, G M Beattie.   

Abstract

To overcome the deleterious effects of hyperglycemia on islet transplantation, we have used recombinant basic fibroblast growth factor (FGF), an angiogenic peptide, concurrently with the intrasplenic placement of neonatal islets in severely diabetic rats. In both experimental and control rats, a minipump, secured to the spleen with a small indwelling catheter, delivered either the basic FGF at 10 ng/hr, or only the diluent. The rate of cure in the animals receiving the islets plus the peptide was significantly higher (70%) than in control rats (20%). This difference (P less than 0.05), could not be attributed to direct effects of the peptide on islet function or to increased islet cell replication. We believe that these results may be best explained as an enhancement by basic FGF of the angiogenic process in the transplant islets.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2256164     DOI: 10.1097/00007890-199012000-00005

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  3 in total

1.  Anchoring of vascular endothelial growth factor to surface-immobilized heparin on pancreatic islets: implications for stimulating islet angiogenesis.

Authors:  Sanja Cabric; Javier Sanchez; Ulrika Johansson; Rolf Larsson; Bo Nilsson; Olle Korsgren; Peetra U Magnusson
Journal:  Tissue Eng Part A       Date:  2010-03       Impact factor: 3.845

Review 2.  Clinical islet cell transplantation. Are we there yet?

Authors:  L Rosenberg
Journal:  Int J Pancreatol       Date:  1998-12

3.  Long-term reversal of diabetes by subcutaneous transplantation of pancreatic islet cells and adipose-derived stem cell sheet using surface-immobilized heparin and engineered collagen scaffold.

Authors:  Yang Hee Kim; Jae Hyung Ko; Song Lee; Ju Yun Oh; Gi Seok Jeong; Si-Nae Park; In Kyong Shim; Song Cheol Kim
Journal:  BMJ Open Diabetes Res Care       Date:  2020-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.